DRUG DELIVERY DEVICE

• US 20140023692A1
• Filed: 11/28/2011
• Published: 01/23/2014
• Est. Priority Date: 11/26/2010
• Status: Abandoned Application

• Current Assignee: University of the Witwatersrand, Johannesburg
• Original Assignee: University of the Witwatersrand, Johannesburg
• Inventors: Du Toit, Lisa Claire, Pillay, Viness, Choonara, Yahya Essop, Govender, Thirumala, Carmichael, Trevor Robin
• Application Number:
  US13/989,401
• Publication Number:
  US 20140023692A1
• Time in Patent Office: Days
• US Class Current: 424/428
• CPC Class Codes: A61K 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The invention provides an inflammation-responsive implantable device for the in situ delivery of one or more pharmaceutically active agents to a human or animal. The device comprises two differential release bioresponsive polymeric matrices (BPMs): an outer polymetric matrix and an inner polymeric matrix, both of which contain at least one pharmaceutically active agent or drug, typically an antibiotic and an anti-inflammatory agent, respectively. The therapeutically effective agent may be embedded in nanoparticles or nanobubbles. In response to inflammation, the pharmaceutically active agents are released, but at different rates: the rate of drug release from the inner polymeric matrix is lower than the rate of drug release from the outer polymeric matrix. Suitable polymers for forming the outer and inner polymeric matrices are hyaluronic acid and chitosan, respectively. A method of making the device and a method of treatment are also described.

Claims

1. An implantable device for the in situ delivery of one or more pharmaceutically active agents to a human or animal, the device comprising:

an outer polymeric matrix formed from at least one inflammation-sensitive polymer and comprising at least one pharmaceutically active agent, wherein the polymer is cross-linked so as to retain the pharmaceutically active agent within the polymeric matrix under normal physiological conditions but undergoes a conformational change when inflammation is present so as to release the pharmaceutically active agent; and

an inner polymeric matrix formed from at least one inflammation-sensitive polymer and comprising at least one pharmaceutically active agent, wherein the polymer is cross-linked so as to retain the pharmaceutically active agent within the polymeric matrix under normal physiological conditions but undergoes a conformational change when inflammation is present so as to release the pharmaceutically active agent;

wherein the inner and outer polymeric matrices are formed so that, when inflammation is present the pharmaceutically active agent within the inner polymeric matrix is released at a slower rate than the pharmaceutically active agent within the outer polymeric matrix.

2. The device according to claim 1, which is an intraocular device for implantation into the eye.

3. The device according to claim 1, wherein the outer polymeric matrix provides fast to intermediate release of the pharmaceutically active agent for the therapeutic management of infection and/or preliminary inflammation, and the inner polymeric matrix provides slower release of the pharmaceutically active agent for chronic responsive management of inflammation.

4. The device according to claim 1, wherein the inner polymeric matrix is chemically modified by cross-linking to provide a slower release rate of the pharmaceutically active agent than the cuter polymeric matrix.

5. The device according to claim 1, which is biodegradable.

6. The device according to claim 1, wherein the polymer of the inner polymeric matrix is a cationic low-molecular weight carbohydrate polymer.

7. The device according to claim 1, wherein the polymer of the inner polymeric matrix is chitosan.

8. The device according to claim 1, wherein the polymer of the outer polymeric matrix is an anionic polymer or a mixture of anionic polymers.

9. The device according to claim 1, wherein the polymer of the outer polymeric matrix is hyaluronic acid.

10. The device according to claim 1, wherein the polymers of the inner and outer polymeric matrices are eroded by free radicals released from activated leukocytes during acute and chronic intraocular inflammatory reactions.

11. The device according to claim 1, wherein each of the polymeric matrices is cross-linked with gluteraldehyde.

12. The device according to claim 11, wherein each of the polymeric matrices is double-crosslinked employing carbodiimide coupling chemistry.

13. The device according to claim 9, wherein the outer polymeric matrix further comprises alginate, polygalacturonate, methylcellulose (polyacetals), poly (ethylene) oxide or poly (acrylic acid).

14. The device according to claim 13, wherein the ratio of alginate:

hyaluronic acid is about 16;

1 and the ratio of alginate;

poly (acrylic acid) is about 4;

1.

15. The device according to claim 11, wherein the ratio of chitosan to the gluteraldehyde cross-linking agent in the inner polymeric matrix is about 7:

1.

16. The device according to claim 1, wherein the pharmaceutically active agent of the outer polymeric matrix is an antibiotic.

17. The device according to claim 1, wherein the pharmaceutically active agent of the outer polymeric matrix is an anti-inflammatory agent.

18. The device according to claim 1, wherein the pharmaceutically active agent of the inner polymeric matrix is an anti-inflammatory agent.

19. The device according to claim 1, wherein the pharmaceutically active agent in the inner polymeric matrix is within or on nanoparticles.

20. The device according to claim 19, wherein the nanoparticles are formed from poly(ε

-caprolactone), chitosan, phospholipids and the pharmaceutically active agent.

21. The device according to either of claim 19 or claim 20, wherein the nanoparticles are nanobubbles.

22. The device according to claim 1, wherein the anti-inflammatory agent is indomethacin.

23. The device according to claim 16, wherein the antibiotic is ciprofloxacin.

24. The device according to claim 1, which defines at least one aperture for suturing the implant to a site in the body.

25. The device according to claim 1, which is for use in preventing or treating inflammatory or infectious conditions in the eye.

26. A device according to claim 1, which is for use in preventing or treating inflammatory or infectious conditions selected from the group consisting of HIV/AIDS, influenza, arthritis, lupus, fibromyalgia, juvenile rheumatoid arthritis, osteomyelitis and septic (infectious) arthritis.

27. A device according to claim 1, which comprises:

an outer polymeric matrix formed from cross-linked hyaluronic acid and comprising an antibiotic, wherein the outer polymeric matrix is eroded when inflammation is present and releases the antibiotic; and

an inner polymeric matrix formed from cross-linked chitosan and comprising nanoparticles which comprise an anti-inflammatory agent, wherein the inner polymeric matrix is eroded when inflammation is present and releases the nanoparticles with the anti-inflammatory agent;

wherein the outer and inner polymeric matrices are prepared so that the pharmaceutically active agent within the inner polymeric matrix, is released at a slower rate than the pharmaceutically active agent within the outer polymeric matrix.

28. A method of manufacturing a device according to claim 1, the method comprising the steps of:

forming nanoparticles from poly(ε

-caprolactone), chitosan, phospholipids and a pharmaceutically active agent;

forming an inner polymeric matrix from the nanoparticles and a polymer which erodes when exposed to inflammation;

forming an outer polymeric matrix from a pharmaceutically active agent and a polymer which erodes when exposed to inflammation, wherein the outer polymeric matrix is designed to erode at a faster rate than the inner polymeric matrix when exposed to inflammation, and so to release the pharmaceutically active agent from the outer polymeric matrix at a faster rate than the inner polymeric matrix;

placing the inner polymeric matrix in an inner portion of a mould;

placing the outer polymeric matrix in an outer portion of the mould;

drying the matrices to form a solid device which is suitable for implantation; and

optionally creating apertures in the device to enable it to be sutured to a site in the body.

29. A method of treating infection and/or inflammation in a human or animal, the method comprising inserting a device as claimed in claim 1 into the human or animal, wherein:

an outer polymeric matrix of the device releases, in the presence of inflammation, a therapeutically effective amount of an antibiotic to treat the infection and preliminary inflammation; and

an inner polymeric matrix of the device releases a therapeutically effective amount of an anti-inflammatory agent at a slower rate than the outer polymeric matrix to treat a chronic inflammatory condition.

30. The method according to claim 29, wherein the infection and/or inflammation is in an eye and the device is inserted into the posterior segment (at the pars plana), or sub-Tenon, or intrasclerally, or on the sclera of the eye.